Phase 2 N=53 Diagnostic

Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

Cancer Diagnosis · Diagnostic Techniques and Procedures · Diagnostic Imaging

Bottom Line

View on ClinicalTrials.gov: NCT03125629 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2021

Primary outcome: Primary: Absolute Accuracy of SUV Max of PET/CT vs PET/MRI — 1.78; 1.08; 0.54; 0.51 ratio

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: F-18 FDG (Drug); Ga-68-DOTA-TATE (Drug); Positron Emission Tomography / Computed Tomography (PET/CT) Scan (Device); Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Stanford University
Primary completion: Nov 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Absolute Accuracy of SUV Max of PET/CT vs PET/MRI	1.78; 1.08; 0.54; 0.51; 0.79; 0.94	—
SECONDARY PET/CT vs PET/MRI Difference in Standardized Uptake Value Max (SUVmax), by Radiotracer	48.95; 5.71; 17.34; 11.24; 3.77; 52.63	—

Summary

This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.

Eligibility Criteria

INCLUSION CRITERIA

Cancer diagnosis
Capable of complying with study procedures
Able to remain still for duration of imaging procedure (approximately 90 minutes total)
Written informed consent

EXCLUSION CRITERIA

Pregnant or nursing
Metallic implants
Impaired renal function

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03125629). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.